

- lu liečiv; 2019 [cited 2026-01-16]. Available from: https://www.sukl.sk/buxus/docs/Bezpecnost_liekov/Pokyny/Definie_zakladnych_pojmov_farmakovigilancie_08_2019_final.pdf.
4. Mann RD, Andrews EB. Pharmacovigilance. 2nd ed. Chichester: John Wiley & Sons; 2007.
 5. Zákon č. 362/2011 Z. z. o liekoch a zdravotníckych pomôckach [Internet]. Zbierka zákonov SR; 2011 [cited 2026-01-17]. Available from: <https://www.slov-lex.sk/pravne-predpisy/SK/ZZ/2011/362/>.
 6. Laššánová M. Základné pojmy. In: Wawruch M, Laššánová M, Tisoňová J, editors. Kapitoly z klinickej farmakológie. 2. vyd. Bratislava: Univerzita Komenského; 2014.
 7. Lassanova M, Liskova S, Tisonova J, et al. Biopharmaceuticals safety perception in Slovakia: considerations and real-life pharmacovigilance data. Bratisl Lek Listy. 2021;122(7):443-448.
 8. Imbrić P, De Bellis M, Liantonio A, et al. Investigating the benefit risk profile of drugs: from spontaneous reporting systems to real world data for pharmacovigilance. Methods Mol Biol. 2025;2834:333-349.
 9. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use [Internet]. 2010 [cited 2026-03-31]. Available from: <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF>.
 10. European Medicines Agency. Good pharmacovigilance practices [Internet]. European Medicines Agency. [cited 2026-01-17]. Available from: <https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices>.
 11. Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency [Internet]. 2010 [cited 2026-03-31]. Available from: <https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF>.
 12. Broekmans AW, Mol PG. Nieuwe wetgeving geneesmiddelenbewaking in de praktijk. Ned Tijdschr Geneesk. 2014;158:A7129.
 13. Štátny ústav pre kontrolu liečiv. Čo znamená označenie obráteného čierneho trojuholníka? [Internet]. Štátny ústav pre kontrolu liečiv. [cited 2026-01-18]. Available from: https://www.sukl.sk/hlavna-stranka/slovenska-verzia/bezpecnost-liekov/hlasenie-podozreni-na-neziaduce-ucinky-liekov/ci-erny-trojuholnik?page_id=3311.
 14. European Medicines Agency. List of medicines under additional monitoring [Internet]. European Medicines Agency; 2025 [cited 2026-01-17]. Available from: <https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring>.
 15. World Health Organization. The WHO Programme for International Drug Monitoring [Internet]. World Health Organization. [cited 2026-01-17]. Available from: <https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/networks/pidm>.
 16. Pal SN, Duncombe C, Falzon D, et al. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36:75-81.
 17. Gupta SK, Srivastava S. Textbook of Pharmacovigilance: Ensuring the Safe Use of Medicines. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers; 2018.
 18. Uppsala Monitoring Centre. The WHO Collaborating Centre for International Drug Monitoring [Internet]. Uppsala Monitoring Centre. [cited 2026-01-16]. Available from: <https://who-umc.org/>.
 19. Drug Safety Matters. Uppsala Reports Long Reads – Weeding out duplicates to better detect side effects [Internet]. Drug Safety Matters; 2024 [cited 2026-01-18]. Available from: <https://www.drugsafetymatterspod.org/618871/episodes/15414766-uppsala-reports-long-reads-weeding-out-duplicates-to-better-detect-side-effects>.
 20. Merrill GH. The MedDRA paradox. AMIA Annu Symp Proc. 2008;2008:470-474.
 21. International Council for Harmonisation. Overview of ICH [Internet]. International Council for Harmonisation; 2023 [cited 2026-01-17]. Available from: https://admin.ich.org/sites/default/files/2023-11/OverviewOfICH_2023_1115_0.pdf.
 22. European Medicines Agency. International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) [Internet]. European Medicines Agency. [cited 2026-01-17]. Available from: <https://www.ema.europa.eu/en/partners-networks/international-activities/multilateral-coalitions-and-initiatives/international-council-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich>.
 23. Kriška M, et al. Riziko liekov v medicínskej praxi. 1. vyd. Bratislava: Slovak Academic Press; 2000.
 24. Jain A, Adenwala Z. The role of artificial intelligence in pharmacovigilance for rare diseases. Expert Opin Drug Saf. 2025;24(8):893-898.
 25. Warner J, Prada Jardim A, Albera C. Artificial intelligence: applications in pharmacovigilance signal management. Pharmaceut Med. 2025;39(3):183-198.
 26. Štátny ústav pre kontrolu liečiv. História a súčasnosť [Internet]. Štátny ústav pre kontrolu liečiv. [cited 2026-01-17]. Available from: https://www.sukl.sk/hlavna-stranka/slovenska-verzia/o-nas/historia-a-sucasnost?page_id=161.
 27. Kriška M, Gajdošík J, Dukát A, et al. Zlyhanie farmakoterapie: možnosti prevencie. 1. vyd. Bratislava: Slovak Academic Press; 2015.
 28. Štátny ústav pre kontrolu liečiv. Výročná správa 2022 [Internet]. Bratislava: ŠÚKL; 2023 [cited 2026-01-16]. Available from: https://www.sukl.sk/buxus/docs/V5_SUKL_2022.pdf.
 29. Jeetu G, Anusha G. Pharmacovigilance: a worldwide master key for drug safety monitoring. J Young Pharm. 2010;2(3):315-320.
 30. Olsson S, Harrison Woolrych M. The role and strategy of ISO-P in global pharmacovigilance. Int J Clin Pharm. 2018;40(4):740-743.
 31. Tyagi S. Global research output in pharmacovigilance (2015-2020). Libr Hi Tech News. 2021;38(9):13-16.
 32. Dang A. Real world evidence: a primer. Pharmaceut Med. 2023;37(1):25-36.
 33. Crisafulli S, Bate A, Brown JS, et al. Interplay of spontaneous reporting and longitudinal healthcare databases for signal management: position statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance. Drug Saf. 2025;48(9):959-976.

S NÁMI SE NEZTRATÍTE

Časopis je indexován v databázích Scopus a Embase

Využíváme systém **CrossRef**. S články můžete snadno pracovat díky jednoznačnému identifikátoru **DOI**.

